✓ Independent editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Home · Guides
Guides

Semaglutide Guides

Released: Last reviewed:

Patient-focused educational guides.

9 guides
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

All guides

503A vs 503B Compounding Pharmacies Explained
Plain-language guide to the difference between 503A patient-specific compounding pharmacies and 503B FDA-registered outsourcing fa Semaglutide Cost Guide — Brand vs Compounded Pricing
Full pricing breakdown: Wegovy pen $349/mo and Wegovy pill $149–$299/mo through NovoCare self-pay, plus compounded semaglutide prices (read October 15, 2026). With insurance, savings, H Semaglutide Side Effects — What Patients Report
Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Mostly mild-moderate, titration-dependent. Manageme Semaglutide Dosing Schedule
Wegovy: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly. Ozempic: 0.25 → 0.5 → 1.0 → 2.0 mg weekly. Rybelsus: 3 → 7 → 14 mg daily oral. BMI Eligibility for Semaglutide Weight Management
Wegovy label: BMI ≥30, or BMI ≥27 with weight-related comorbidity. 2024 expansion: adults with overweight/obesity + established CV Compounded vs Brand-Name Semaglutide
Made with the drug in Wegovy and Ozempic, not the same product. Brand: FDA-approved; Wegovy is $349/mo through NovoCare self-pay and the Wegovy pill $149–$299/mo (read October 15, 2026). Compounded: not FDA-approved; month-to-month examples include $87 (Mondae) and $99 (Eden), read October 15, 2026, and $109 (NexLife, as of November 6, 2026). Quality verified through Semaglutide Insurance Coverage
Brand Wegovy is covered by many commercial plans for BMI documentation; Medicare Part D expanded for CV indication in 2024. Compou How Semaglutide Works — Mechanism Explained
Semaglutide activates the GLP-1 receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, redu Semaglutide and Cardiovascular Health
Semaglutide is the first GLP-1 with an FDA-approved CV indication for non-diabetic patients. SELECT trial: 20% MACE reduction in n

Tirzepatide guides (new)

Semaglutide guides

Reference